Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Advances in Inflammation & Allergy Drug Discovery
  4. Volume 19, Issue 1
  5. Article
Volume 19, Issue 1
  • ISSN: 2772-2708
  • E-ISSN: 2772-2716

Abstract

Over the world, millions of individuals suffer from psoriasis, a chronic inflammatory skin disease. It is caused by a multifaceted mixture of environmental, immunological, and genetic factors. This review explores the many aspects of psoriasis, where the introduction gives a context background, emphasizing the prevalence and difficulties that people encounter with this dermatological ailment. Further, the pathogenesis complex systems involving immunological dysregulation, genetic susceptibility, and triggers are clarified, providing insights into the disease's fundamental mechanisms. Examining drugs shows how, over time, therapy modalities have evolved, moving from traditional topical treatments to the introduction of biologics and small molecules. The continuous efforts to control symptoms, reduce inflammation, and improve patient outcomes are highlighted in this section. Furthermore, a thorough review of patents reveals the creative advancements made in the sector, highlighting encouraging advancements in treatment modalities and potential paths forward. This manuscript is a review article and is based on various research and review articles. We have summarized the salient features and findings from different articles and prepared this manuscript.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708307214240628042627
2024-07-10
2025-05-08

  • From This Site

    /content/journals/raiad/10.2174/0127722708307214240628042627
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KamiyaK. KishimotoM. SugaiJ. KomineM. OhtsukiM. Risk factors for the development of psoriasis.Int. J. Mol. Sci.20192018434710.3390/ijms2018434731491865
     [Google Scholar]
  2. KumarD. RajguruJ.P. MayaD. SuriP. BhardwajS. PatelN. Update on psoriasis: A review.J. Family Med. Prim. Care202091202410.4103/jfmpc.jfmpc_689_1932110559
     [Google Scholar]
  3. World Health OrganizationGlobal report on psoriasis.2016Available From: https://www.who.int/publications/i/item/ 9789241565189
  4. DograS. MahajanR. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.Indian Dermatol. Online J.20167647148010.4103/2229‑5178.19390627990381
     [Google Scholar]
  5. MichalekI.M. LoringB. JohnS.M. A systematic review of worldwide epidemiology of psoriasis.J. Eur. Acad. Dermatol. Venereol.201731220521210.1111/jdv.1385427573025
     [Google Scholar]
  6. FurueM. YamazakiS. JimbowK. TsuchidaT. AmagaiM. TanakaT. MatsunagaK. MutoM. MoritaE. AkiyamaM. SomaY. TeruiT. ManabeM. Prevalence of dermatological disorders in Japan: A nationwide, cross-sectional, seasonal, multicenter, hospital-based study.J. Dermatol.201138431032010.1111/j.1346‑8138.2011.01209.x21426384
     [Google Scholar]
  7. CharalambousH. BloomfieldD. Psoriasis and radiotherapy: Exacerbation of psoriasis following radiotherapy for carcinoma of the breast (the Koebner phenomenon).Clin. Oncol.200012319219310942338
     [Google Scholar]
  8. MüllerH. FähJ. DummerR. Unusual Koebner phenomenon in psoriasis caused by varicella and UVB.Hautarzt19974821301329173061
     [Google Scholar]
  9. MoraisP. OliveiraM. MatosJ. Striae: A potential precipitating factor for Koebner phenomenon in psoriasis?Dermatol. Online J.20131951818610.5070/D319501818624011283
     [Google Scholar]
  10. WeissG. ShemerA. TrauH. The Koebner phenomenon: Review of the literature.J. Eur. Acad. Dermatol. Venereol.200216324124810.1046/j.1473‑2165.2002.00406.x12195563
     [Google Scholar]
  11. KathuriaS. PuriP. NandarS.K. RameshV. Effects of air pollution on the skin: A review.Indian J. Dermatol. Venereol. Leprol.201783441542310.4103/0378‑6323.19957928195077
     [Google Scholar]
  12. LiawF.Y. ChenW.L. KaoT.W. ChangY.W. HuangC.F. Exploring the link between cadmium and psoriasis in a nationally representative sample.Sci. Rep.201771172310.1038/s41598‑017‑01827‑928496169
     [Google Scholar]
  13. GunesA.T. FetilE. AkarsuS. OzbagcivanO. BabayevaL. Possible triggering effect of influenza vaccination on psoriasis.J. Immunol. Res.201520151410.1155/2015/25843026380315
     [Google Scholar]
  14. WeeJ.S. NatkunarajahJ. MoosaY. MarsdenR.A. Erythrodermic pustular psoriasis triggered by intravesical bacillus Calmette-Guérin immunotherapy.Clin. Exp. Dermatol.201237445545710.1111/j.1365‑2230.2011.04183.x22582918
     [Google Scholar]
  15. MaciasV.C. CunhaD. Psoriasis triggered by tetanus-diphtheria vaccination.Cutan. Ocul. Toxicol.201332216416510.3109/15569527.2012.72793623050604
     [Google Scholar]
  16. YoneyamaS. KamiyaK. KishimotoM. KomineM. OhtsukiM. Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine.J. Dermatol.20194611e442e44310.1111/1346‑8138.1500731271448
     [Google Scholar]
  17. van der FitsL. MouritsS. VoermanJ.S.A. KantM. BoonL. LamanJ.D. CornelissenF. MusA.M. FlorenciaE. PrensE.P. LubbertsE. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.J. Immunol.200918295836584510.4049/jimmunol.080299919380832
     [Google Scholar]
  18. BonigenJ. Raynaud-DonzelC. HureauxJ. KramkimelN. BlomA. JeudyG. BretonA.L. HubicheT. BedaneC. LegoupilD. Pham-LedardA. CharlesJ. PérolM. GérardE. CombemaleP. BonnetD. SigalM.L. MahéE. Anti-PD 1-induced psoriasis: A study of 21 patients.J. Eur. Acad. Dermatol. Venereol.2017315e254e25710.1111/jdv.1401127739129
     [Google Scholar]
  19. KimD.W. ParkS.K. WooS.H. YunS.K. KimH.U. ParkJ. New-onset psoriasis induced by rituximab therapy for non-Hodgkin lymphoma in a child.Eur. J. Dermatol.201626219019110.1684/ejd.2015.270526771919
     [Google Scholar]
  20. FryL. BakerB.S. Triggering psoriasis: The role of infections and medications.Clin. Dermatol.200725660661510.1016/j.clindermatol.2007.08.01518021899
     [Google Scholar]
  21. MallonE. BunkerC.B. HIV-associated psoriasis.AIDS Patient Care STDS200014523924610.1089/10872910031769610833810
     [Google Scholar]
  22. LeeE.J. HanK.D. HanJ.H. LeeJ.H. Smoking and risk of psoriasis: A nationwide cohort study.J. Am. Acad. Dermatol.201777357357510.1016/j.jaad.2017.04.01528807112
     [Google Scholar]
  23. BrenautE. HorreauC. PouplardC. BarnetcheT. PaulC. RichardM.A. JolyP. Le MaîtreM. AractingiS. AubinF. CribierB. JullienD. OrtonneJ.P. MiseryL. Alcohol consumption and psoriasis: A systematic literature review.J. Eur. Acad. Dermatol. Venereol.201327Suppl. 3303510.1111/jdv.1216423845150
     [Google Scholar]
  24. MurzakuEC BronsnickT RaoBK Diet in dermatology: Part II. Melanoma, chronic urticaria, and psoriasis.J. Am. Acad. Dermatol.2014716e11053-e11053-e16
     [Google Scholar]
  25. GisondiP. FostiniA.C. FossàI. GirolomoniG. TargherG. Psoriasis and the metabolic syndrome.Clin. Dermatol.2018361212810.1016/j.clindermatol.2017.09.00529241748
     [Google Scholar]
  26. CarrascosaJ.M. RocamoraV. Fernandez-TorresR.M. Jimenez-PuyaR. MorenoJ.C. Coll-PuigserverN. FonsecaE. Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications.Actas Dermosifiliogr.20141051314410.1016/j.adengl.2012.08.02423177976
     [Google Scholar]
  27. MamizadehM. TardehZ. AzamiM. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis.Diabetes Metab. Syndr.20191321405141210.1016/j.dsx.2019.01.00931336500
     [Google Scholar]
  28. TakahashiH. IizukaH. Psoriasis and metabolic syndrome.J. Dermatol.201239321221810.1111/j.1346‑8138.2011.01408.x22035413
     [Google Scholar]
  29. KimH.N. HanK. SongS.W. LeeJ.H. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study.PLoS One2018138e020285410.1371/journal.pone.020285430142208
     [Google Scholar]
  30. YangH. ZhengJ. Influence of stress on the development of psoriasis.Clin. Exp. Dermatol.202045328428810.1111/ced.1410531592542
     [Google Scholar]
  31. EversA.W.M. VerhoevenE.W.M. KraaimaatF.W. De JongE.M.G.J. De BrouwerS.J.M. SchalkwijkJ. SweepF.C.G.J. Van De KerkhofP.C.M. How stress gets under the skin: Cortisol and stress reactivity in psoriasis.Br. J. Dermatol.2010163598699110.1111/j.1365‑2133.2010.09984.x20716227
     [Google Scholar]
  32. LehmannM. SchornoP. HungerR.E. HeidemeyerK. FeldmeyerL. YawalkarN. New onset of mainly guttate psoriasis after COVID-19 vaccination: A case report.J. Eur. Acad. Dermatol. Venereol.20213511e752e75510.1111/jdv.1756134309932
     [Google Scholar]
  33. DuffinK.C. HwangS.T. KruegerJ.G. Advances and controversies in our understanding of guttate and plaque psoriasis.J. Rheumatol.2023502Suppl. 24710.3899/jrheum.2023‑050037657796
     [Google Scholar]
  34. PfingstlerL.F. MaroonM. MowadC. Guttate psoriasis outcomes.Cutis201697214014426919501
     [Google Scholar]
  35. TengY XieW TaoX LiuN YuY HuangY XuD FanY. Infection provoked psoriasis: Induced or aggravated.Exp. Thera. Med.202121619
     [Google Scholar]
  36. MaulJ.T. AnzengruberF. ConradC. CozzioA. HäusermannP. JaliliA. KoliosA.G.A. LaffitteE. LapointeA.K. MainettiC. SchlapbachC. TrüebR. YawalkarN. DippelM. NavariniA.A. Topical treatment of psoriasis vulgaris: The Swiss treatment pathway.Dermatology2021237216617810.1159/00051293033406520
     [Google Scholar]
  37. GriffithsC.E.M. ArmstrongA.W. GudjonssonJ.E. BarkerJ.N.W.N. Psoriasis.Lancet2021397102811301131510.1016/S0140‑6736(20)32549‑633812489
     [Google Scholar]
  38. ArmstrongA.W. ReadC. Pathophysiology, clinical presentation, and treatment of psoriasis: A review.JAMA2020323191945196010.1001/jama.2020.400632427307
     [Google Scholar]
  39. JiC. WangH. BaoC. ZhangL. RuanS. ZhangJ. GongT. ChengB. Challenge of nail psoriasis: An update review.Clin. Rev. Allergy Immunol.202161337740210.1007/s12016‑021‑08896‑934478047
     [Google Scholar]
  40. ThomasL. AzadJ. TakwaleA. Management of nail psoriasis.Clin. Exp. Dermatol.20214613810.1111/ced.1431432741010
     [Google Scholar]
  41. StewartC.R. AlguL. KamranR. LeveilleC.F. AbidK. RaeC. LipnerS.R. The impact of nail psoriasis and treatment on quality of life: A systematic review.Skin Appendage Disord.202172838910.1159/00051268833796553
     [Google Scholar]
  42. HadelerE. MoscaM. HongJ. BrownstoneN. BhutaniT. LiaoW. Nail psoriasis: A review of effective therapies and recommendations for management.Dermatol. Ther.202111379983110.1007/s13555‑021‑00523‑x33978917
     [Google Scholar]
  43. MicaliG. VerzìA.E. GiuffridaG. PanebiancoE. MusumeciM.L. LacarrubbaF. Inverse psoriasis: From diagnosis to current treatment options.Clin. Cosmet. Investig. Dermatol.2019121295395932099435
     [Google Scholar]
  44. JfriA. LeungB. SaidJ.T. SemenovY. LeBoeufN.R. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.Immunother. Adv.202221ltac01610.1093/immadv/ltac01636196370
     [Google Scholar]
  45. HongJ.J. MoscaM.L. HadelerE.K. BrownstoneN.D. BhutaniT. LiaoW.J. Genital and inverse/intertriginous psoriasis: An updated review of therapies and recommendations for practical management.Dermatol. Ther.202111383384410.1007/s13555‑021‑00536‑633914293
     [Google Scholar]
  46. BachelezH. Pustular psoriasis: The dawn of a new era.Acta Derm. Venereol.20201003879310.2340/00015555‑338831971600
     [Google Scholar]
  47. GooderhamM.J. Van VoorheesA.S. LebwohlM.G. An update on generalized pustular psoriasis.Expert Rev. Clin. Immunol.201915990791910.1080/1744666X.2019.164820931486687
     [Google Scholar]
  48. DharS. SrinivasS. Psoriasis in pediatric age group.Indian J. Dermatol.202267437438010.4103/ijd.ijd_570_2236578742
     [Google Scholar]
  49. ShaoS. WangG. MaverakisE. GudjonssonJ.E. Targeted treatment for erythrodermic psoriasis: Rationale and recent advances.Drugs202080652553410.1007/s40265‑020‑01283‑232180204
     [Google Scholar]
  50. LoY. TsaiT.F. Updates on the treatment of erythrodermic psoriasis.Psoriasis202111597310.2147/PTT.S28834534136373
     [Google Scholar]
  51. MegnaM. PotestioL. FabbrociniG. CinelliE. Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?Dermatol. Ther.2021345e1503010.1111/dth.1503034137492
     [Google Scholar]
  52. DograS. MehtaH. Biological treatment for erythrodermic psoriasis.Expert Opin. Biol. Ther.202222121531154310.1080/14712598.2022.212866936154361
     [Google Scholar]
  53. de AlcantaraC.C. ReicheE.M.V. SimãoA.N.C. Cytokines in psoriasis.Adv. Clin. Chem.202110017120410.1016/bs.acc.2020.04.00433453865
     [Google Scholar]
  54. WangA. BaiY. Dendritic cells: The driver of psoriasis.J. Dermatol.202047210411310.1111/1346‑8138.1518431833093
     [Google Scholar]
  55. HuP. WangM. GaoH. ZhengA. LiJ. MuD. TongJ. The role of helper T cells in psoriasis.Front. Immunol.20211278894010.3389/fimmu.2021.78894034975883
     [Google Scholar]
  56. KruegerG. EllisC.N. Psoriasis—recent advances in understanding its pathogenesis and treatment.J. Am. Acad. Dermatol.2005531Suppl. 1S94S10010.1016/j.jaad.2005.04.03515968269
     [Google Scholar]
  57. LawsP.M. YoungH.S. Topical treatment of psoriasis.Expert Opin. Pharmacother.201011121999200910.1517/14656566.2010.49277820569091
     [Google Scholar]
  58. ChengY. KongF. Low molecular weight protamine-corticosteroid conjugate for topical treatment of psoriasis: A hypothesis.Med. Hypotheses202216011077610.1016/j.mehy.2022.110776
     [Google Scholar]
  59. MaiY. OuyangY. YuM. QinY. GirardiM. SaltzmanW.M. CoccoE. ZhaoC. YuL. JiaY. XiaoL. DouL. DengW. LiuY. XieJ. DengY. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis.J. Control. Release202234935436610.1016/j.jconrel.2022.07.00635817278
     [Google Scholar]
  60. BarreaL. SavanelliM.C. Di SommaC. NapolitanoM. MegnaM. ColaoA. SavastanoS. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist.Rev. Endocr. Metab. Disord.201718219520510.1007/s11154‑017‑9411‑628176237
     [Google Scholar]
  61. SatheP. SakaR. KommineniN. RazaK. KhanW. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.Drug Dev. Ind. Pharm.201945582683810.1080/03639045.2019.157672230764674
     [Google Scholar]
  62. DadwalA. MishraN. RawalR.K. NarangR.K. Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis.J. Microencapsul.202037534135410.1080/02652048.2020.175697032293928
     [Google Scholar]
  63. FeldmanS.R. YentzerB.A. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations.Am. J. Clin. Dermatol.200910639740610.2165/11311020‑000000000‑0000019824740
     [Google Scholar]
  64. TaylorA. SinghR. FeldmanS.R. Review of calcipotriene and betamethasone dipropionate cream in the treatment of psoriasis.Ann. Pharmacother.202357334134710.1177/1060028022110550835730211
     [Google Scholar]
  65. PurvisC.G. BaloghE.A. HeronC.E. FeldmanS.R. Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: A drug evaluation.Expert Opin. Pharmacother.20212291107111810.1080/14656566.2021.190082533745399
     [Google Scholar]
  66. FereigS.A. El-ZaafaranyG.M. ArafaM.G. Abdel-MottalebM.M.A. Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis.Carbohydr. Polym.202126811823810.1016/j.carbpol.2021.11823834127220
     [Google Scholar]
  67. RaiV.K. RoyA. SharmaA. RathG. KarB. GhoshG. PradhanD. HalderJ. Development and pharmaceutical evaluation of azelaic acid and vitamin E oil-based nanoemulgel of tacrolimus for topical application in plaque psoriasis.J. Pharm. Innov.20231841616162510.1007/s12247‑023‑09740‑7
     [Google Scholar]
  68. Erolİ. Üstündağ OkurN. OrakD. SipahiH. AydınA. ÖzerÖ. Tazarotene-loaded in situ gels for potential management of psoriasis: Biocompatibility, anti-inflammatory and analgesic effect.Pharm. Dev. Technol.202025890991810.1080/10837450.2020.176518032364036
     [Google Scholar]
  69. SidgiddiS. AllenbyK. OkumuF. GautamA. Bioavailability, pharmacokinetics, and transepidermal water loss of short contact tazarotene lotion 0.1% versus tazarotene (Tazorac®) cream 0.1%.J. Clin. Aesthet. Dermatol.2019129162431641413
     [Google Scholar]
  70. KeményL. VargaE. NovakZ. Advances in phototherapy for psoriasis and atopic dermatitis.Expert Rev. Clin. Immunol.201915111205121410.1080/1744666X.2020.167253731575297
     [Google Scholar]
  71. LiY. CaoZ. GuoJ. LiQ. ZhuW. KuangY. ChenX. Assessment of efficacy and safety of UV-based therapy for psoriasis: A network meta-analysis of randomized controlled trials.Ann. Med.202254115916910.1080/07853890.2021.202218734989291
     [Google Scholar]
  72. KennethB.G. ThomasS.M. Evolution of biologic therapies for the treatment of psoriasis.Dermatol. Clin.200325286294
     [Google Scholar]
  73. ÖzyurtK. ErtaşR. AtasoyM. Biologics for psoriasis: What is new?Dermatol. Ther.2019323e1291610.1111/dth.1291630972872
     [Google Scholar]
  74. SubediS. GongY. ChenY. ShiY. Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events.Drug Des. Devel. Ther.2019132491250210.2147/DDDT.S20014731413544
     [Google Scholar]
  75. TanJ.K. AphaleA. MalaviyaR. SunY. GottliebA.B. Mechanisms of action of etanercept in psoriasis.J. Investig. Dermatol. Symp. Proc.2007121384510.1038/sj.jidsymp.565003717502868
     [Google Scholar]
  76. ShannonE. DaffyJ. JonesH. PaulsonA. VicikS. Etanercept (Enbrel®>) alternative storage at ambient temperature.Clin. Pharmacol.20179879910.2147/CPAA.S13183228790869
     [Google Scholar]
  77. AlwawiE.A. MehlisS.L. GordonK.B. Treating psoriasis with adalimumab.Ther. Clin. Risk Manag.20084234535118728850
     [Google Scholar]
  78. MoorkensE. GodmanB. HuysI. HoxhaI. MalajA. KeuerleberS. StockingerS. MörtenhuberS. DimitrovaM. TachkovK. VončinaL. PalčevskiV.V. AchniotouG. SlabýJ. PopelkováL. KohoutováK. BartelsD. LaiusO. MartikainenJ.E. SelkeG.W. KourafalosV. MagnússonE. EinarsdóttirR. AdamsR. JoppiR. AllocatiE. JakupiA. ViksnaA. Greičiūtė-KuprijanovI. Vella BonannoP. SuttorpV. MelienØ. PliskoR. MardareI. MeshkovD. NovakovicT. FürstJ. ZaraC. Marković-PekovićV. GrubišaN. BefritsG. PuckettR. VultoA.G. The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in Europe: An overview of pricing and national policy measures.Front. Pharmacol.20211159113410.3389/fphar.2020.59113433519450
     [Google Scholar]
  79. JenneckC. NovakN. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis.Ther. Clin. Risk Manag.20073341142018488075
     [Google Scholar]
  80. FinlayA.Y. SalekM.S. HaneyJ. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.Dermatology2003206430731510.1159/00006994212771471
     [Google Scholar]
  81. McIntoshS.M. KerutC. HollensheadP.P. AskinsD.H. MansourianK. PalowskyZ.R. AllampalliV. AhmadzadehS. ShekoohiS. KayeA.D. Golimumab for polyarticular juvenile idiopathic arthritis and psoriatic arthritis: Pharmacologic and clinical considerations.Life (Basel)2023137160110.3390/life1307160137511975
     [Google Scholar]
  82. FeloL. Otero-LobatoM. GeldhofA. NoëlW. Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan.Ther. Adv. Drug Saf.201910.10.1177/204209861984742031205675
     [Google Scholar]
  83. Wcisło-DziadeckaD. GrabarekB. Kruszniewska-RajsC. Strzałka-MrozikB. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.Dermatol. Ther.2019323e1284310.1111/dth.1284330693647
     [Google Scholar]
  84. BuckinghamR. SiderS. CococcioniL. ElZeinA. ChadokufaS. ShahN. OcholiA. BorrelliO. KiparissiF. N24 experience with ustekinumab (STELARA®>) in Paediatric inflammatory bowel disease (pIBD) – A case series.J. Crohn’s Colitis2019131Suppl. 1S56810.1093/ecco‑jcc/jjy222.1012
     [Google Scholar]
  85. ChimentiM.S. SaracenoR. ChiricozziA. GiuntaA. ChimentiS. PerriconeR. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.Drug Des. Devel. Ther.2013733934810.2147/DDDT.S3165823620660
     [Google Scholar]
  86. GoelN. StephensS. Certolizumab Pegol.MAbs20102213714710.4161/mabs.2.2.1127120190560
     [Google Scholar]
  87. CampbellK. LiK. YangF. BraniganP. EllosoM.M. BensonJ. OrlovskyY. ChenY. GarcetS. KruegerJ.G. Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab.Immunohorizons20237427328510.4049/immunohorizons.230000337071038
     [Google Scholar]
  88. CannonL. PanA. KovalickL. SarkissianA. WuE.Y. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies.Ann. Allergy Asthma Immunol.2023130671872610.1016/j.anai.2023.02.01036801438
     [Google Scholar]
  89. GhazawiF.M. MahmoodF. KircikL. PoulinY. BourcierM. VenderR. WisemanM.C. LyndeC. LitvinovI.V. A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab.Front. Med.2021870277610.3389/fmed.2021.70277634447766
     [Google Scholar]
  90. KolbingerF. Di PadovaF. DeodharA. HawkesJ.E. HuppertzC. KuiperT. McInnesI.B. RitchlinC.T. RosmarinD. SchettG. CarballidoJ.M. HäusermannP. CalonderC. VogelB. RondeauJ.M. BruinG. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.Pharmacol. Ther.202222910792510.1016/j.pharmthera.2021.10792534171337
     [Google Scholar]
  91. StrychalskiM.L. BrownH.S. BishopS.C. Cytokine modulators in plaque psoriasis – a review of current and prospective biologic therapeutic approaches.JAAD Int.20229829110.1016/j.jdin.2022.08.00836248203
     [Google Scholar]
  92. CraigS. WarrenR.B. Ixekizumab for the treatment of psoriasis: Up-to-date.Expert Opin. Biol. Ther.202020654955710.1080/14712598.2020.172973632050819
     [Google Scholar]
  93. TaoR.E. PixleyJ.N. HolovachP.G. FleischerA.B. FeldmanS.R. Management of pediatric psoriasis: A us survey based on visits from the National Ambulatory Medical Care Survey (NAMCS).Dermatol. Ther.2023131710.1007/s13555‑023‑01051‑637831297
     [Google Scholar]
  94. CaputoV. StrafellaC. CosioT. LannaC. CampioneE. NovelliG. GiardinaE. CascellaR. Pharmacogenomics: An update on biologics and small-molecule drugs in the treatment of psoriasis.Genes2021129139810.3390/genes1209139834573380
     [Google Scholar]
  95. TorresT. FilipeP. Small molecules in the treatment of psoriasis.Drug Dev. Res.201576521522710.1002/ddr.2126326255795
     [Google Scholar]
  96. ChiricozziA. SaracenoR. NovelliL. FidaM. CasoF. ScarpaR. CostaL. PerriconeR. RomanelliM. ChimentiS. ChimentiM.S. Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015).Expert Opin. Ther. Pat.2016267757669
     [Google Scholar]
  97. GooderhamM. Small molecules: An overview of emerging therapeutic options in the treatment of psoriasis.Skin Therapy Lett.20131871424305752
     [Google Scholar]
  98. AbdulrahimH. SharlalaH. AdebajoA.O. An evaluation of tofacitinib for the treatment of psoriatic arthritis.Expert Opin. Pharmacother.201920161953196010.1080/14656566.2019.165740431456440
     [Google Scholar]
  99. XuZ. WangY. LiuZ. ZhangR. ZhouY. YuJ. LanJ. LiangW. LiuG. QuX. ChenJ. SuZ. YuS. ChengY. WangW. RenQ. DengQ. ZhaoY. YangH. A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz®> in Chinese healthy subjects.Int. Immunopharmacol.202210910878010.1016/j.intimp.2022.10878035461158
     [Google Scholar]
  100. LannaC. CesaroniG.M. MazzilliS. VollonoL. GazianoR. MarinoD. BianchiL. CampioneE. Apremilast as a target therapy for nail psoriasis: A real-life observational study proving its efficacy in restoring the nail unit.J. Dermatolog. Treat.20223321097110110.1080/09546634.2020.180197632715817
     [Google Scholar]
  101. AbushalA.S. AleanizyF.S. AlqahtaniF.Y. ShakeelF. IqbalM. HaqN. AlsarraI.A. Self-nanoemulsifying drug delivery system (SNEDDS) of apremilast: In vitro evaluation and pharmacokinetics studies.Molecules20222710308510.3390/molecules2710308535630561
     [Google Scholar]
  102. LebwohlM.G. PappK.A. Stein GoldL. GooderhamM.J. KircikL.H. DraelosZ.D. KempersS.E. ZirwasM. SmithK. OsborneD.W. TrotmanM.L. NavaleL. MerrittC. BerkD.R. WelgusH. Trial of roflumilast cream for chronic plaque psoriasis.N. Engl. J. Med.2020383322923910.1056/NEJMoa200007332668113
     [Google Scholar]
  103. PixleyJ.N. SchaetzleT. FeldmanS.R. A review of topical roflumilast for the treatment of plaque psoriasis.Ann. Pharmacother.202357896696910.1177/1060028022113775036420929
     [Google Scholar]
  104. KingstonP. BlauveltA. StroberB. ArmstrongA.W. Deucravacitinib: A novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.J. Psoriasis Psoriatic Arthritis20238415616510.1177/2475530323120133638188537
     [Google Scholar]
  105. van der KraaijG. BusardC. van den ReekJ. MentingS. MustersA. HuttenB. de RieM. OuwerkerkW. van BezooijenS.J. PrensE. RispensT. de VriesA. de JongE. de KortW. LambertJ. van DoornM. SpulsP. Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial.J. Invest. Dermatol.2022142923752383.e610.1016/j.jid.2022.01.03335276223
     [Google Scholar]
  106. CrowleyJ. ThaçiD. JolyP. PerisK. PappK.A. GoncalvesJ. DayR.M. ChenR. ShahK. FerrándizC. CatherJ.C. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).J. Am. Acad. Dermatol.2017772310317.e110.1016/j.jaad.2017.01.05228416342
     [Google Scholar]
  107. SvendsenM.T. AndersenF. AndersenK.H. AndersenK.E. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial.BMC Dermatol.2018181210.1186/s12895‑018‑0071‑329415699
     [Google Scholar]
  108. ReichK. WarrenR.B. IversenL. PuigL. Pau-CharlesI. IgarashiA. OhtsukiM. FalquésM. HarmutM. RozzoS. LebwohlM.G. CantrellW. BlauveltA. ThaçiD. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks.Br. J. Dermatol.2020182360561710.1111/bjd.1823231218661
     [Google Scholar]
  109. MerolaJ.F. ParishL.C. GuentherL. LyndeC. LacourJ.P. StaubachP. ChengS. ParisM. PicardH. DeignanC. JardonS. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.J. Am. Acad. Dermatol.2023881937852306
     [Google Scholar]
  110. CrowleyJ.J. LangleyR.G. GordonK.B. PinterA. FerrisL.K. RubantS. PhotowalaH. XueZ. WuT. ZhanT. BeeckS. ShahM. WarrenR.B. Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: Subgroup analysis from the IMMerge study.Dermatol. Ther.202212256157510.1007/s13555‑021‑00679‑635050485
     [Google Scholar]
  111. WarrenR.B. BlauveltA. PoulinY. BeeckS. KellyM. WuT. GengZ. PaulC. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial.Br. J. Dermatol.20211841505910.1111/bjd.1934132594522
     [Google Scholar]
  112. BlauveltA. KimballA.B. AugustinM. OkuboY. WitteM.M. CaprilesC.R. SontagA. AroraV. OsuntokunO. StroberB. Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).Br. J. Dermatol.2022187686687710.1111/bjd.2174335791755
     [Google Scholar]
  113. FaurschouA. GyldenløveM. RohdeU. ThyssenJ.P. ZachariaeC. SkovL. KnopF.K. VilsbøllT. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial.J. Eur. Acad. Dermatol. Venereol.201529355555910.1111/jdv.1262925139195
     [Google Scholar]
  114. KangE.G. WuS. GuptaA. von MackensenY.L. SiemetzkiH. FreudenbergJ.M. Wigger-AlbertiW. YamaguchiY. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.Br. J. Dermatol.201817861427142910.1111/bjd.1613129150844
     [Google Scholar]
  115. TehlirianC. SinghR.S.P. PradhanV. RobertsE.S. TarabarS. PeevaE. VincentM.S. GaleJ.D. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.J. Am. Acad. Dermatol.202287233334210.1016/j.jaad.2022.03.05935398218
     [Google Scholar]
  116. AngsanaJ. BraniganP. DePrimoS. FlavinS. LiS. LiuX. MunozE. RandazzoB. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody.US Patent 20200157209A12023
  117. DowG.J. PillaiR. BhattV.D. Topical compositions and methods for treating psoriasis.US Patent 11648256B22023
  118. KimC.H. LeeY.S. LeeM.H. Composition pour le traitement d'atopie ou de psoriasis comprenant un plasma en phase liquide.WO Patent 2018056665A22023
  119. SunL. ZhenQ. LiB. Application of agent in preparation of medicine for treating/inhibiting psoriasis.US Patent 176458952023
  120. ChanD. ChoiO. GaoL.L. JeyarajahJ. LiS. RowlandK. SinhaV. WangY. Method of treating psoriasis with IL-23 specific antibody.AU Patent 2017362222A12023
  121. AvramN. Compositions for treatment of psoriasis of the scalp.US Patent 20230110297A12023
  122. JainM. JoharapurkarA. PatelV. Treatment for psoriasis and skin inflammatory diseases.EP Patent 4157233A12023
  123. KimJ.C. BanzragchD. LeeE.H. HongS.C. HamJ.Y. ParkY.T. NhoC.W. Composition for ameliorating psoriasis symptoms containing extract of sphallerocarpus gracilis.US Patent 20220080011A12023
  124. LiM. TolcherA.W. PRMT5 inhibitor for use in a method of treating psoriasis and other autoimmune conditions.US Patent 177584682023
  125. KrausJ.E. LeeJ. Use of tapinarof for the treatment of chronic plaque psoriasis.US Patent 20200147000A12023
  126. SilverM.E. Method for treating psoriasis.US Patent 20230233505A112023
  127. HsuM.C. LiS. RandazzoB. SongK. ZhuY. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody.US Patent 179316332023
  128. BlanzatM. JebbawiR. PoupotR. TurrinC.O. SimonM. ClementE. LabieH. OukhribA. Anti-inflammatory dendrimer formulation for the treatment of psoriasis.AU Patent 2020412366A12023
/content/journals/raiad/10.2174/0127722708307214240628042627
Loading
Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends
Rec Adv Inflamm Allergy Drug Discov 19, 31 (2025); https://doi.org/10.2174/0127722708307214240628042627
/content/journals/raiad/10.2174/0127722708307214240628042627
/content/journals/raiad/10.2174/0127722708307214240628042627
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): autoimmune disorder; biologics; chronic skin disease; Psoriasis; T-cells; topical treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test